Excelon IP

Excelon IP We help you protect your innovation and creativity theough Intellectual property rights like Patent, Trademark, Design Patent and Copyrights.

Know more at https://youtube.com/

23/08/2026

Ek promising molecule mil gaya… but patent file karne se pehle disclose kar diya toh?

Pharma R&D mein patent strategy product launch ke time start nahi hoti.

It can start right from the discovery stage.

Jaise hi research team ko promising molecule ya invention identify hota hai, patent filing ka timing extremely important ho sakta hai.

Because agar filing se pehle invention conference, research paper ya kisi public platform par disclose ho jaaye toh woh disclosure patentability ko impact kar sakta hai.

Uske baad journey continue hoti hai:

Discovery → Patent Filing → Pre-clinical → Clinical Trials → Regulatory Approval → Market Launch → IP Commercialisation

Aur market launch ke baad strong IP portfolio company ko apne years of R&D investment se commercial value create karne mein help karta hai.

That’s why pharma mein IP sirf protection nahi—poore innovation lifecycle ki strategy hai.

Aapke according pharma companies ko patent team ko kis stage par involve karna chahiye?

Comment below.

[ pharma patent strategy, drug discovery, patent filing, pharmaceutical R&D, intellectual property, public disclosure, patentability, drug development lifecycle, preclinical trials, clinical trials, regulatory approval, pharma innovation, biotech patents, IP strategy, pharmaceutical commercialization, patent protection, life sciences IP ]

Heading to Hamburg for the 2026 AIPPI World Congress. We are pleased to share that Sanjaykumar Patel, Founder & Principa...
21/08/2026

Heading to Hamburg for the 2026 AIPPI World Congress.

We are pleased to share that Sanjaykumar Patel, Founder & Principal IP Attorney, will be attending the 2026 AIPPI World Congress from 7–10 October 2026.

Looking forward to connecting with the global IP community, exchanging insights, and building meaningful professional relationships in Hamburg.

📍 Congress Center Hamburg, Germany
📅 7–10 October 2026

Want to connect or schedule a meeting with Sanjaykumar Patel during the Congress?
📩[email protected]

See you in Hamburg!

20/08/2026

Biosimilars mein India sirf participate nahi kar raha — global game mein apni position build kar raha hai.

Biocon ka trastuzumab example ek important lesson deta hai.

Original biologic ka patent expire hone ke baad opportunity open hoti hai—but sirf biosimilar develop karna enough nahi hai.

Apna manufacturing process develop karna, us process ke around strong IP build karna, aur manufacturing advantage create karna can become a powerful global strategy.

Aur Biocon ke alawa bhi Indian pharma companies biosimilar space mein aggressively grow kar rahi hain.

Big takeaway:
Biosimilars mein advantage sirf lower cost ka nahi.

It's
Process + IP + Manufacturing = Competitive Edge.

Aapko kya lagta hai—can India become a global biosimilar leader? Comment below.

[ India biosimilars, Biocon biosimilars, trastuzumab biosimilar, Herceptin biosimilar, biosimilar industry India, pharmaceutical IP strategy, process patents pharma, biologics manufacturing, Indian biotech industry, affordable biologics, biosimilar development, pharma patent strategy, biotechnology innovation, Indian pharmaceutical companies, IP strategy in pharma ]

18/08/2026

Generic aur biosimilar SAME cheez nahi hain.

Generic drug ko hum reference drug ke close equivalent ke form mein samajh sakte hain — same active ingredient, strength, dosage form aur route ke saath bioequivalence demonstrate karna hota hai.

Lekin Biosimilar = exact copy nahi.

Biologics living systems se manufacture hote hain, isliye manufacturing aur batch-to-batch level par natural variations possible hoti hain.

Isi liye biosimilar ko technically “highly similar” kaha jata hai — reference biologic ke identical nahi, but clinically meaningful difference bhi nahi hona chahiye.

Aur yahi difference pharma IP aur biosimilar strategy ko much more interesting bana deta hai.

Aapko pehle Generic vs Biosimilar ka ye difference pata tha?

Save karo & Pharma/IP field ke kisi person ke saath share karo.

[ generic vs biosimilar, generic drug, biosimilar, biologics, generic medicine, reference biologic, pharma IP, pharmaceutical patents, biosimilar development, biologic drugs, patent strategy, biotechnology, pharmaceutical industry, drug development, intellectual property, biosimilar explained ]

16/08/2026

Ek drug ko protect karne ke liye 130+ patents?

Humira patent thicket iska one of the most famous examples hai.

Sirf ek basic patent nahi—formulation, treatment, dosage, combination, process, device aur product ke different aspects around multiple patents ka portfolio create kiya ja sakta hai.

Humira ke case mein U.S. patent portfolio itna extensive tha ki biosimilar competitors ke liye market entry ka patent landscape extremely complex ho gaya. Court records have referred to 132 additional Humira-related patents held by AbbVie.

Isi dense web of patent rights ko commonly “Patent Thicket” kaha jata hai.

One product. Multiple layers of IP protection.

Aapke according ye strong IP strategy hai ya excessive patenting? Comment your view

[ Humira patent thicket, Humira patents, AbbVie Humira, patent thicket explained, pharmaceutical patent strategy, biotech patents, biologics patents, biosimilar competition, pharma IP strategy, intellectual property strategy, drug patent protection, pharmaceutical patents, biosimilar market entry, patent portfolio, life sciences IP ]

13/08/2026

₹2.80 lakh ki monthly cancer therapy, sirf ₹8,800 mein—kaise?

2012 mein Natco Pharma ne Bayer ke patented cancer drug Nexavar ke liye compulsory licence apply kiya.

Natco ka case teen important points par based tha:

— Public ki requirement adequately meet nahi ho rahi thi
— Medicine reasonably affordable price par available nahi thi
— Patented invention India mein “worked” nahi thi

Indian Patent Office ne compulsory licence grant kar diya.

Lekin iska matlab patent cancel hona nahi tha. Natco ko specific conditions ke saath medicine manufacture aur sell karne ka legal right mila, jabki Bayer ko royalty milti rahi.

Yeh India ka pehla aur ab tak Section 84 ke under eklauta granted compulsory licence hai.

Aapke according, life-saving medicines ke case mein patent protection aur public access ke beech yeh balance sahi hai?

Comment karke batayein—and is landmark IP case ko save kar lijiye.

[ Compulsory licensing in India, Nexavar case explained, Natco vs Bayer, Section 84 Patents Act, pharmaceutical patent law, affordable cancer medicines, sorafenib tosylate, access to medicines India, Indian Patent Office, patent rights and public interest, landmark IP case India, compulsory licence example ]

11/08/2026

Patent mil gaya…

Patent owner ko exclusive rights milte hain—but public interest ko completely ignore nahi kiya ja sakta.

Agar patented invention:

• public ki reasonable requirements meet nahi kar raha,
• reasonably affordable price par available nahi hai, ya
• India mein properly “worked” nahi ho raha,

toh Section 84 ke under compulsory licence seek kiya ja sakta hai—generally patent grant hone ke 3 years baad.

Interested applicant ordinarily pehle reasonable terms par voluntary licence obtain karne ki effort karta hai. Agar reasonable period mein agreement nahi hota, toh woh Indian Patent Office ke Controller ko approach kar sakta hai.

Lekin compulsory licence automatic nahi milta. Grounds, capability aur public benefit establish karna padta hai.

Aur ek important point: compulsory licence milne ka matlab patent cancel hona nahi hai.

Patent rights powerful hain—but absolute nahi.

Aapke according, innovation protection aur public access ke beech right balance kya hona chahiye? Comment karke batayein—and save this for future reference.

[ Compulsory licensing in India, Indian Patent Act Section 84, patent monopoly, voluntary licence, patent affordability, patented product accessibility, working of patents in India, generic manufacturers, pharmaceutical patents, Indian Patent Office, patent owner rights, public interest in patent law, IP law explained, patent licensing India, Excelon IP ]

09/08/2026

Sirf crystal form badalne se kisi medicine par naya patent mil sakta hai?

Novartis ne cancer drug imatinib mesylate ke beta-crystalline form ke liye India mein patent protection claim kiya tha.

Lekin asli sawaal yeh tha: kya yeh sirf known substance ka modified form tha, ya isse therapeutic efficacy mein real enhancement hua tha?

Section 3(d) ke under improved stability, physical properties ya bioavailability dikhana apne aap mein enough nahi hai. New form ko enhanced therapeutic efficacy establish karni hoti hai.

Novartis Glivec judgment ne isi principle ko clarify kiya aur pharmaceutical patent evergreening ki debate mein ek landmark precedent ban gaya.

Aapke hisaab se Section 3(d) innovation aur public interest ke beech right balance create karta hai? Comment karke batayein.

[ Novartis Glivec case, Section 3(d), imatinib mesylate, beta-crystalline form, Indian patent law, pharmaceutical patents, enhanced therapeutic efficacy, patent evergreening, landmark IP case, Supreme Court patent judgment ]

07/08/2026

Kya medicine mein chhota-sa change karke 20 saal ka naya patent mil sakta hai?

Maan lijiye ek company ke drug ka patent expire hone wala hai. Company usi drug ka salt, crystal form ya particle size change karke naya patent claim karti hai.

Lekin India mein sirf “form naya hai” kehna enough nahi hai.

Section 3(d) ke under company ko scientific data se dikhana hoga ki change se efficacy mein significant improvement hua hai. Pharmaceutical drug ke case mein focus meaningful therapeutic improvement par hota hai.

Agar modification insignificant hai, toh patent nahi milega. Isi safeguard ko pharmaceutical evergreening ke against ek important protection maana jata hai.

Section 3(d) innovation ko stop nahi karta—genuine improvement aur minor modification ke beech difference establish karta hai.

Aapke according, innovation aur affordable medicines ke beech right balance kya hona chahiye? Comment karke batayein aur kisi pharma ya IP professional ke saath share karein.

[ Section 3(d), Section 3D explained, patent evergreening, pharmaceutical patents India, Indian Patents Act, drug patent modification, therapeutic efficacy, generic medicines, affordable medicines, pharma patent law, patent monopoly, incremental innovation, IP law India ]

05/08/2026

Same medicine, alag process—patent infringement ya legal?

Yahin se product patent aur process patent ka real difference samajh aata hai.

Product patent product itself ko protect karta hai—sirf manufacturing process change karke uski protection avoid nahi ki ja sakti.

Process patent ek specific manufacturing method ko protect karta hai. Isliye genuinely different aur non-infringing process se wahi product banana possible ho sakta hai—provided product khud kisi valid product patent se protected na ho.

India ke 1970 patent framework mein medicines ke liye product patents allowed nahi the. Is process-patent model ne Indian generic pharma industry ki growth mein important role play kiya.

Phir WTO-TRIPS commitments ke baad 2005 mein pharmaceutical product patent regime introduce hua—and Indian pharma business ke rules fundamentally change ho gaye.

Aapke hisaab se India ki “Pharmacy of the World” journey mein is policy ka kitna role tha? Comment karo aur kisi pharma ya IP professional ke saath share karo.

[ Product patent vs process patent, Indian patent law, Patents Act 1970, Patents Amendment Act 2005, pharmaceutical patents India, WTO TRIPS Agreement, Indian pharma industry, generic medicines India, Pharmacy of the World, pharma IP strategy, patent education, pharma law explained ]

Address

627, Gala Empire, Drive In Rd, Thaltej
Ahmedabad
380054

Website

Alerts

Be the first to know and let us send you an email when Excelon IP posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Excelon IP:

Shortcuts

Share

Category